Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 2Phase NA 1Phase 1/2 1

Status

Withdrawn 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Lymphoma 1Hodgkin Disease 1

Interventions

Cyclophosphamide 47Rituximab 34Exercise 25fludarabine phosphate 24Methotrexate 24Blood Specimen Collection 23Vincristine 21Cytarabine 21Radiotherapy 20Filgrastim 19Peripheral Blood Stem Cell Transplantation 18Whole-Body Irradiation 17Prednisone 16Melphalan 16Etoposide 16Cyclosporine 16Methods 15Dexamethasone 15Busulfan 15Antilymphocyte Serum 15fludarabine 14Doxorubicin 14Educational Status 13Mycophenolic Acid 12Magnetic Resonance Spectroscopy 11Early Intervention, Educational 11Therapeutics 10Surveys and Questionnaires 9Standard of Care 9Prednisolone 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase NA × B3(Fv)-PE38KDEL recombinant immunotoxin × Lymphoid × Clear all
NCT00389506 2012-03-16

Fludarabine and Cyclophosphamide Followed By LMB-2 Immunotoxin in Treating Patients With Hodgkin's Lymphoma

National Institutes of Health Clinical Center (CC)

Phase NA Withdrawn
Lymphoid

Hodgkin Disease, Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡